Journal of Clinical Endocrinology & Metabolism, Vol 76, 1182-1187, Copyright © 1993 by Endocrine Society

ARTICLES

Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor

MB Zimering, N Katsumata, Y Sato, ML Brandi, GD Aurbach, SJ Marx and HG Friesen
Metabolic Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892.

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by tumors of the parathyroids, pancreatic islets, and anterior pituitary. We previously reported a basic fibroblast growth factor (bFGF)-like substance in the plasma of subjects with MEN1. In the present study we used a novel sensitive specific 2-site immunoradiometric assay to test for bFGF in plasma. The assay employs immobilized affinity-purified N-terminal-specific anti- bFGF antibodies (antigen capture) and high affinity binding to radioiodinated heparin. bFGF-like immunoreactivity was undetectable (< 0.2 ng/mL) in normal subjects and in most unaffected relatives of MEN1 subjects. We found detectable bFGF ranging from 0.24-1.28 ng/mL in 21 of 50 subjects with MEN1. Seven of 8 MEN1 subjects with untreated pituitary tumors had detectable plasma bFGF-like immunoreactivity. Plasma bFGF-like immunoreactivity decreased after surgery for pituitary tumor in 4 patients and after initiation of bromocryptine therapy in 4 patients. bFGF was increased in the plasma of several subjects with sporadic endocrine disorders, including 3 with untreated or persistent acromegaly. We conclude that pituitary tumor is a possible source of high circulating bFGF immunoreactivity in MEN1 plasma.

This article has been cited by other articles:

				S. Ezzat, L. Zheng, D. Winer, and S. L. Asa Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications Mol. Endocrinol., November 1, 2006; 20(11): 2965 - 2975. [Abstract] [Full Text] [PDF]

				J. Tfelt-Hansen, D. Kanuparthi, and N. Chattopadhyay The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin. Med. Res., June 1, 2006; 4(2): 130 - 137. [Abstract] [Full Text] [PDF]

				A. P. Heaney Pituitary tumour pathogenesis. Br. Med. Bull., January 1, 2006; 75-76: 81 - 97. [Abstract] [Full Text] [PDF]

				S Ezzat and S L Asa The molecular pathogenetic role of cell adhesion in endocrine neoplasia J. Clin. Pathol., November 1, 2005; 58(11): 1121 - 1125. [Abstract] [Full Text] [PDF]

				S. Ezzat, L. Zheng, and S. L. Asa Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia Mol. Endocrinol., October 1, 2004; 18(10): 2543 - 2552. [Abstract] [Full Text] [PDF]

				H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass Angiogenesis in Endocrine Tumors Endocr. Rev., October 1, 2003; 24(5): 600 - 632. [Abstract] [Full Text] [PDF]

				S. L. Asa, L. Ramyar, P. R. Murphy, A. W. Li, and S. Ezzat The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production Mol. Endocrinol., April 1, 2001; 15(4): 589 - 599. [Abstract] [Full Text]

				X. Zhang, G. A. Horwitz, A. P. Heaney, M. Nakashima, T. R. Prezant, M. D. Bronstein, and S. Melmed Pituitary Tumor Transforming Gene (PTTG) Expression in Pituitary Adenomas J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 761 - 767. [Abstract] [Full Text]

				X. Zhang, G. A. Horwitz, T. R. Prezant, A. Valentini, M. Nakashima, M. D. Bronstein, and S. Melmed Structure, Expression, and Function of Human Pituitary Tumor-Transforming Gene (PTTG) Mol. Endocrinol., January 1, 1999; 13(1): 156 - 166. [Abstract] [Full Text]

				S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]

				R. E. Schweppe, A. A. Frazer-Abel, A. Gutierrez-Hartmann, and A. P. Bradford Functional Components of Fibroblast Growth Factor (FGF) Signal Transduction in Pituitary Cells. IDENTIFICATION OF FGF RESPONSE ELEMENTS IN THE PROLACTIN GENE J. Biol. Chem., December 5, 1997; 272(49): 30852 - 30859. [Abstract] [Full Text] [PDF]

				I. Shimon and S. Melmed Pituitary Tumor Pathogenesis J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681. [Full Text] [PDF]

				D. J. Hill, A. Flyvbjerg, E. Arany, F. F. Lauszus, and J. G. Klebe Increased Levels of Serum Fibroblast Growth Factor-2 in Diabetic Pregnant Women with Retinopathy J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1452 - 1457. [Abstract] [Full Text] [PDF]

				D. Ray and S. Melmed Pituitary Cytokine and Growth Factor Expression and Action Endocr. Rev., April 1, 1997; 18(2): 206 - 228. [Abstract] [Full Text]

				J.-W. Gu, D. Santiago, Y. Olowe, and J. Weinberger Basic Fibroblast Growth Factor as a Biochemical Marker of Exercise-Induced Ischemia Circulation, March 4, 1997; 95(5): 1165 - 1168. [Abstract] [Full Text]